Skip to content

Mapping the Uterine Cervix Stiffness of Pregnant Women at Mid Gestation

MAPVIX: Mapping the Uterine Cervix Stiffness of Pregnant Women at Mid Gestation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05858775
Acronym
MAPVIX
Enrollment
30
Registered
2023-05-15
Start date
2023-07-05
Completion date
2025-10-10
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervix; Pregnancy

Keywords

Cervical Stiffness

Brief summary

The assessment of cervical stiffness plays a major role in obstetrics, for example to assess the risk of preterm birth. The Pregnolia System is a CE-certified measuring device that objectively determines cervical stiffness using a slight negative pressure. The Pregnolia System was developed in Switzerland and resulted from a research project of the ETH and the University Hospital Zurich. Until now, the stiffness of the cervix was examined and individually assessed by palpation (palpation with fingers). The Pregnolia System was developed to make this measurement objective and independent of the examining person. The aim of the study is to measure cervical stiffness at different locations on the cervix to see if there are differences between the measurement locations.

Interventions

Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.

Sponsors

Pregnolia AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Informed Consent signed by the subject * Pregnant woman at GA 16+0 - 22+6 * Singleton pregnancy * 18 years or older * Nulliparous cohort: nulliparous pregnant woman * Multiparous cohort: multiparous pregnant woman

Exclusion criteria

* Lack of informed consent * Placenta praevia * Severe vaginal bleeding * Rupture of membranes before 34 weeks (to be excluded with pH test) * Visible tissue scarring at the measurement locations\* on cervix * Light bleeding (if the bleeding can be stopped, it is no longer an exclusion criterion) * Cervical dilation ≥ 3 cm * Cerclage or pessary in place * Vaginal or cervical infections (to be excluded with the Amsel criteria)

Design outcomes

Primary

MeasureTime frameDescription
Cervical Stiffness Index at 16+0 - 22+616+0 - 22+6 gestational weeksCervical Stiffness Index (CSI, in mbar) measured at 3 locations on the cervix (approximately 12, 4 and 8 o'clock, in a random order) at mid-pregnancy (16+0 - 22+6 gestational weeks).

Secondary

MeasureTime frameDescription
Cervical Stiffness Index (repetition)16+0 - 22+6 gestational weeks and optional follow-up visitsCervical Stiffness Index (CSI, in mbar) measured 3 times at each location
Cervical Stiffness Index (cohort)16+0 - 22+6 gestational weeks and optional follow-up visitsCervical Stiffness Index (CSI, in mbar) for each cohort.
Delivery data1-4 weeks after delivery or termination of the pregnancyDelivery data

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026